New drug cocktail targets tough cancers in early trial

NCT ID NCT03065062

Terminated Disease control Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a combination of two targeted drugs, palbociclib and gedatolisib, in people with advanced lung, pancreatic, head & neck, or other solid tumors that have stopped responding to standard treatments. The main goal is to find the safest dose and look for early signs that the drugs can control tumor growth. About 75 participants will take part, and the trial is currently on hold.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Palbociclib and Gedatolisib (two targeted cancer drugs)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced solid tumors that have not responded to standard therapies.
What could go wrong: This is a very early Phase 1 trial, so the main goal is just finding a safe dose. It is too soon to know if the combination will actually shrink tumors or improve survival, and side effects are expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometrium neoplasm exocrine pancreatic carcinoma head and neck cancer Head and Neck Neoplasms malignant pancreatic neoplasm neoplasm pancreatic neoplasm squamous cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEAD NECK CANCER LUNG CANCER SQUAMOUS CELL PANCREATIC CANCER SOLID TUMORS

Contacts and locations

Locations

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02115, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02115, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.